Navigation Links
International Travel Raises Risk of Typhoid
Date:8/25/2009

Drug-resistant strains most common among visitors to Indian subcontinent, CDC reports

TUESDAY, Aug. 25 (HealthDay News) -- International travel is the most common cause of infection with an antimicrobial-resistant strain of typhoid fever among patients in the United States, a new study finds.

About 300 cases of typhoid fever are reported in the United States each year, and the majority of these cases are associated with foreign travel, especially to India, Pakistan and Bangladesh. Over the last 20 years, the emergence of Salmonella serotype Typhi strains resistant to antimicrobial drugs has complicated the treatment of patients in the United States, according to researchers at the U.S. Centers for Disease Control and Prevention.

The CDC team studied data on 1,902 people, median age 22, treated for typhoid fever in the United States between 1999 and 2006, and examined the test results of 2,016 Salmonella Typhi samples submitted to the CDC for analysis.

The researchers found that 1,295 (73 percent) of the patients were hospitalized and three (0.2 percent) died. They also found that 1,439 (79 percent) of the patients had traveled overseas within 30 days before they became ill, and only 58 of the travelers (5 percent) had received typhoid vaccine.

Three countries accounted for more than two-thirds of all travel-associated cases of typhoid fever -- India (47 percent), Pakistan (10 percent) and Bangladesh (10 percent).

The study appears in the Aug. 26 issue of the Journal of the American Medical Association.

The researchers also found that "272 [13 percent] of 2,016 isolates tested were resistant to ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole [multidrug-resistant S. Typhi]; 758 [38 percent] were resistant to nalidixic acid [nalidixic acid-resistant S. Typhi [NARST]], and 734 NARST isolates [97 percent] had decreased susceptibility to ciprofloxacin. The proportion of NARST increased from 19 percent in 1999 to 54 percent in 2006," Dr. Michael F. Lynch, of the CDC, and colleagues wrote in a news release from the journal.

Resistant infections were most likely to occur in patients who had traveled to the Indian subcontinent. These patients accounted for 85 percent of multidrug-resistant S. Typhi infections, 94 percent of nalidixic acid-resistant infections and 44 percent of susceptible infections, the researchers noted.

"Since most typhoid fever among patients treated in the United States is acquired abroad, ongoing surveillance may also help track global patterns of antimicrobial resistance of S. Typhi. Reducing the burden of typhoid fever in the United States will require increased attention to prevention measures by travelers, including improved vaccination coverage among travelers to typhoid-endemic areas," the authors concluded. "Further reductions in typhoid fever among travelers will depend on increased availability of safe drinking water as well as improved sanitation and food hygiene in typhoid endemic areas, measures that would go a long way toward reducing the global burden of typhoid fever."

More information

The CDC has more about typhoid fever.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, Aug. 25, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. TBI/Tissue Banks International and Northwest Tissue Services Announce Collaborative Distribution Agreement
2. HBA Global Announces Finalists for the 2009 International Package Design Awards (IPDA)
3. Jani-King Recognized as Best in Support by the International Business Awards
4. The Donor Source International, LLC Opens Office in New England
5. International Micro Industries (IMI) is ITAR Registered
6. Dallas Physician Elected to Lead International Organ Transplant Society
7. HeartWare International Surpasses 50 Implants in the US
8. Former GE Executive Joins Lifeclinic International
9. Chindex International, Inc. Announces New CDC Contract
10. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
11. Reliv International Launches New Products and Business Tools at 21st International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
International Travel Raises Risk of Typhoid  
(Date:1/23/2017)... ... January 23, 2017 , ... Ultimate ... K-20 Education Summit to be held March 23-25, 2017 in Tampa, and reminded ... 2017. , The keynote speakers include Dr. Michelle R. Weise, executive director of ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water ... educate listeners about the benefits of making new water infrastructure a number one priority. ... appropriate that we expect water infrastructure to become a top priority of our new ...
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, makers of all-natural ... USDA National Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. ... and handling systems to complement our current rigorous food-safety management systems,” said Yishu ...
(Date:1/23/2017)... ... ... a story of love and redemption, hope and uncertainty as a girl makes her ... Inn at the Mill” is the creation of published author, Lois Kulp, who was born ... Berks County on Crow Hill. The inn, the mill and "Post Yokel" are ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Valentine’s Day is a time when many people ... ones. For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic ... get an additional $25 free. Or, spend $200 and get $50 free. , “A ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , January 20, 2017 According to ... (Descriptive, Prescriptive), Application (Marketing, R&D, Compliance, SCM), Component (Software, Service), Delivery ... Forecasts to 2021" published by MarketsandMarkets, the market is expected to ... 2016, at a CAGR of 13.3% during the forecast period. ... ...
(Date:1/21/2017)... Mass. , Jan. 20, 2017 /PRNewswire/ ... Keystone Symposia Conference, "PI3K Pathways in Immunology, ... Inc. (NASDAQ: INFI ) ... immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma ... able to help overcome resistance to checkpoint ...
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
Breaking Medicine Technology: